期刊文献+

英夫利西单抗治疗17例中重度寻常性银屑病 被引量:4

原文传递
导出
摘要 银屑病是一种在多基因遗传因素与环境因素相互作用的基础上,由T淋巴细胞介导的免疫性慢性炎症性皮肤病,可并发多种系统性疾病,也可严重影响患者心理健康。目前认为肿瘤坏死因子(α(TNF-α)等前炎症因子在银屑病的发病机制中发挥了作用。英夫利西单抗是一种针对TNF—α的人鼠嵌合型单克隆抗体,可以阻断TNF—α与免疫活性细胞表面的TNF—α受体结合,抑制机体的炎症反应,达到控制病情的目的。我们观察英夫利西单抗治疗寻常性银屑病的疗效和安全性。
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2016年第6期437-438,共2页 Chinese Journal of Dermatology
基金 北京市自然科学基金(7103175) 北京协和医院中青年基金(PUMCH-2013-125)
  • 相关文献

参考文献7

  • 1Schrn MP, Boehncke WH. Psoriasis[J]. N Engl J Med, 2005, 352 (18): 1899-1912. DOI: 10.1056/NEJMra041320.
  • 2Luber AJ, Tsui CL, Heinecke GM, et al. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis [J]. J Am Acad Dermatol, 2014, 70 (3): 525-532. DOI: 10.1016/j.jaad. 2013.10.059.
  • 3Dotan I, Ran Y, Yanai H, et al. Patient factors that increase infli- ximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study [J]. Inflamm Bowel Dis, 2014, 20 (12): 2247-2259. DOI: 10.1097/MIB. 0000000000000212.
  • 4Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double- blind, placebo-controlled trial [J]. J Am Acad Dermatol, 2004, 51 (4): 534-542. DOI: 10.1016/j.jaad.2004.02.021.
  • 5Wetter DA, Davis MD. Lupus-like syndrome attributable to anti- tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic [ J ]. Mayo Clin Proc, 2009, 84 ( 11 ): 979-984. DOI: 10.4065/84.11.979.
  • 6朱晨雨,孙秋宁,舒畅,李芸,樊雪,张心瑜,陈典.英夫利西单抗治疗重度银屑病17例临床观察[J].中华皮肤科杂志,2016,49(4):294-295. 被引量:5
  • 7Zhu Chenyu, Sun Qiuning, Shu Chang, et al. Infliximab for the treatment of severe psoriasis in 17 cases: a clinical observational study[J]. Chin J Dermatol, 2016, 49(4): 294-295. DOI: 10.3760/ ema.j .issn.0412-4030.2016.04.021.

二级参考文献10

  • 1Gottlieb AB, Chamian F, Masud S, et down-regulates muhiple proinflammatow pathways in psoriasis plaques [ J. ] Immunol, 2005, 175 (4): 2721-2729. DOI: l 0.4049/ jimmunol. 175.4.2721.
  • 2Kimber 1, Cumberbatch M, Dearman RJ, et al. Cytokines and chenmkines in the initiation anti regulation of epidermal Langerhans cell mobilization [J ]. Br J Demlatol. 2000, 142 ( 3 ): 401-412. DOI: 10.1046/j.1365-2133.2000.03349.x.
  • 3Langley RG, Strober BE, Gu Y, et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis [J ]. Br J Dermatol, 2010, 162 (6): 1349-1358. DOI: 10.1111/j.1365- 2133.2010.09707.x.
  • 4Ahmad K, Rogers S. Three years' experience with infliximab in recalcitrant psoriasis[J]. Clin Exp Dermatol, 2006, 31 ( 5 ): 630- 633. DOI: 10.111 l/j.1365-2230.2006.02170.x.
  • 5Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referr',d centre [J ]. Br J Dennatol, 2009, 160 (1): 162-169. DOI: 10.1111/j.1365- 2133.2008.08865.x.
  • 6Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis[J]. J Am Aead Dermatol, 2007, 56( 1 ): 31. DOI: 10.1016/ j.jaad.2006.07.017.
  • 7Fahroni C, Gori A, Troiano M, et al. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients [J]. J Eur Acad Demlatol Venereol, 2011, 25 (5): 549-553. DOI: 10.1111/j.1468- 3083.2010.03826.x.
  • 8G6mez-Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection [J]. Arthritis Rheum, 2007, 57 (5): 756-761. DOI: 10.1002/art.22768.
  • 9余晓玲,晋红中.英夫利西单抗治疗关节病性银屑病进展[J].中华皮肤科杂志,2014,47(3):223-225. 被引量:3
  • 10张堂德,李琳琳,罗妙璇.英夫利西单抗治疗寻常性银屑病七例[J].中华皮肤科杂志,2015,48(6):438-439. 被引量:3

共引文献4

同被引文献47

引证文献4

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部